Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2951742 in Knee Osteoarthritis Pain
NCT02192190Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2014
- Primary completion
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of galcanezumab in osteoarthritis (OA), sponsored by Eli Lilly and Company. Started Jul 2014; status: terminated.
02
Drugs
galcanezumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02192190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192190.